Phase 1 N=27 Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing
Breast Neoplasms · Breast Cancer · Adenocarcinomas
Primary: Number of Participants With Cardiac Toxicity — 6; 7; 6; 6 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=8 Trial of IRE in Cholangiocarcinoma
Cholangiocarcinoma
Primary: Number of Patients Experiencing a Clinically Relevant Complications — 1; 7 Participants
Phase 2 N=363 An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
Primary: Number of Participants Who Meet Response Criteria for Systemic Lupus Erythematosus (SLE) Responder Index [SRI(4)] at Week 32 — 31; 53; 46; 40 Participants — p=0.0006
Phase 4 N=223 A Phase IV Safety and Efficacy Study of VI-0521 in Adolescents With Obesity
Adolescent Obesity · Obesity in Adolescence · Adolescent Overweight
Primary: Mean % Change in Body Mass Index (BMI) — 3.34; -4.78; -7.11 Percentage Change — p=<0.0001
N/A N=110 Enhanced E-cigarette Coaching Intervention for Dual Users of Cigarettes and E-cigarettes
Smoking Cessation
Primary: Treatment Satisfaction and Acceptability Measured on a Scale From 1-6 (Very Satisfied to Very Dissatisfied) — 5.5; 5.0 units on a scale
Phase 3 N=522 Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type
Agitation in Participants With Dementia of the Alzheimer's Type
Primary: Change From Baseline to Week 12 in the Cohen-Mansfield Agitation Inventory (CMAI) Composite Score — 73.7; 68.8; 71.3; -16.2 score on a scale — p=0.789
N/A N=86 Wall Shear Stress and Neointimal Healing Following PCI in Angulated Coronary Vessels
Coronary Artery Disease
Primary: In Stent Mean Cross-sectional Area of Neo-intimal Tissue Coverage — 1.381; 0.949 mm^2
N/A N=86 Cannabinoid Control of Fear Extinction Neural Circuits in Post-traumatic Stress Disorder
Post-Traumatic Stress Disorder
Primary: Brain Measures — -0.08; 0.27; 0.02; 0.03 arbitrary units — p=>0.05
Phase 2 N=72 Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).
Melanoma
Primary: Objective Response Rate (ORR) Per Modified RECIST v1.1 — 3.8; 6.7; 40.0; 46.7 Percentage of Participants
N/A N=4,160 Developing and Evaluating Product Messaging
Cancer of Colon · Cancer of Rectum
Primary: Count of Products That Contain Red Meat — 3.5; 3.2; 3.1; 2.7 red meat products — p=0.002
Phase 3 N=331 A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis
ANCA-Associated Vasculitis
Primary: Percentage of Subjects Achieving Disease Remission at Week 26 — 70.1; 72.3 percentage of participants — p=< 0.0001
Phase 4 N=49 N-of-1 Trials In Children With Hypertension
Pediatric Hypertension
Primary: Number of Participants With Ambulatory Blood Pressure (BP) Control at 6 Months — 8; 8; 10; 15 Participants
Phase 2 N=197 A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis
Liver Fibrosis · Nonalcoholic Fatty Liver Disease (NAFLD) · Nonalcoholic Steatohepatitis
Primary: The Percentage of Participants With Improvement in Fibrosis or Nonalcoholic Steatohepatitis (NASH) at Week 24 — 30.6; 24.0; 26.5; 14.3 Percentage of Participants — p=0.055
N/A N=17 18F-FLT-PET Imaging of the Brain in Patients With Metastatic Breast Cancer to the Brain Treated With Whole Brain Radiation Therapy With or Without Sorafenib: Comparison With MR Imaging of the Brain
Metastatic Breast Cancer to the Brain
Primary: Overall Response Rate — 71 % of pts w/complete or partial response
Phase 4 N=17 Optimal Morphine Dosing Schedule for Neonatal Abstinence Syndrome
Neonatal Abstinence Syndrome · Neonatal Opioid Withdrawal · Neonatal Opioid Withdrawal Syndrome
Primary: Enrollment Rate — 17 Participants